Transcriptome sequencing reveals novel biomarkers and immune cell infiltration in esophageal tumorigenesis
Jian-Rong Sun, Rong Huang, Rui-Tao Wang, School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
Dong-Mei Chen, Li-Qun Jia, Integrated Chinese and Western Medicine Oncology, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Sun JR and Jia LQ designed the study and modified the manuscript; Sun JR and Chen DM carried out the data extraction and statistical analysis; Sun JR, Chen DM, Huang R, and Wang RT drafted the manuscript; and all authors contributed to the article and approved the submitted version.
Supported by National Natural Foundation of China, No. 82174223; and 2019 Chinese and Western Medicine Clinical Collaborative Capacity Building Project for Major Difficult Diseases, No. 2019-ZX-005.
Institutional review board statement: The research involving human tissue samples was approved by the Institutional Ethics Committee of Cixian Cancer Hospital (2019-CXCH-19) and China-Japan Friendship Hospital (2019-190-K131).
Institutional animal care and use committee statement: All the animal procedures and experiments conducted in the current study were approved by the Animal Ethics Committee of the China-Japan Friendship Hospital (Permit No. ZRDWLL20230210).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Li-Qun Jia, MD, Chief Doctor, Professor, Integrated Chinese and Western Medicine Oncology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing 100029, China. liqun_jia@hotmail.com
Received: November 21, 2023
Peer-review started: November 21, 2023
First decision: December 27, 2023
Revised: January 7, 2024
Accepted: February 4, 2024
Article in press: February 4, 2024
Published online: April 15, 2024
